Gemcitabine

製品コードS1714 別名:LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW):263.2

Gemcitabineは一種の有効で、特異性的なデオキシシチジン(deoxycytidine)類似物で、、化学療法として使用されることです。

サイズ 価格(税別) 在庫  
JPY 21580.00 あり
JPY 16102.00 あり

カスタマーフィードバック(4)

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabineは一種の有効で、特異性的なデオキシシチジン(deoxycytidine)類似物で、、化学療法として使用されることです。
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPTOWdKSzVyPUCuNFAxPDV6IH7N NHTmcnFUSU6JRWK=
ES4 NV\LV4p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrFZ4NPUUN3ME2wMlAxODZ3MzDuUS=> NYnpd2JXW0GQR1XS
ACHN NIP4UmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:3O2l3UUN3ME2wMlAxODh6NzDuUS=> Ml2xV2FPT0WU
KYSE-510 MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMECwPVc2KG6P MlrGV2FPT0WU
EW-7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;ydJhoUUN3ME2wMlAxOjV6IH7N NHLzcFNUSU6JRWK=
BFTC-905 NIP5XFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjVO4pKSzVyPUCuNFA2OTVibl2= NXrQPWk1W0GQR1XS
KE-37 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nxemlEPTB;MD6wNFU3OSCwTR?= NXjRW5gxW0GQR1XS
SBC-5 M1\vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEC1O{BvVQ>? NFriPGpUSU6JRWK=
NKM-1 NHz5WY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPpTWM2OD1yLkCwO|A6KG6P MXHTRW5ITVJ?
RH-1 M3y1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\TU2lEPTB;MD6wNFcyQCCwTR?= MVfTRW5ITVJ?
ALL-PO MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrRNmNGUUN3ME2wMlAxQDNibl2= MWjTRW5ITVJ?
QIMR-WIL NHf0N4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fJT2lEPTB;MD6wNFg6PCCwTR?= M{DWdXNCVkeHUh?=
A375 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKy[nN7UUN3ME2wMlAxQTl3IH7N NEjpepRUSU6JRWK=
SIG-M5 NY\HZo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEGwOEBvVQ>? Mme1V2FPT0WU
KGN M4P3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHudWJKSzVyPUCuNFExQCCwTR?= Mlr5V2FPT0WU
EW-13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPhbVBiUUN3ME2wMlAyOTJibl2= MUjTRW5ITVJ?
NCI-SNU-1 NIDlTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLiTWM2OD1yLkCxOkBvVQ>? M2i5c3NCVkeHUh?=
PSN1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fmNGlEPTB;MD6wNVY2KG6P M1\2XXNCVkeHUh?=
HUTU-80 M1\nNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n1XGlEPTB;MD6wNVY3KG6P NFK3UWpUSU6JRWK=
EW-16 NV:zSpVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\2XmlEPTB;MD6wNlMhdk1? MmPRV2FPT0WU
786-0 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHpTWM2OD1yLkCyN{BvVQ>? MlfhV2FPT0WU
ES1 M17tXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OxTGlEPTB;MD6wNlY5KG6P M2nWVnNCVkeHUh?=
RKO M3PZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPjeItKUUN3ME2wMlAzPzlibl2= NFfoXGNUSU6JRWK=
ESS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\xbWlEPTB;MD6wNlg3KG6P MXjTRW5ITVJ?
SK-UT-1 M4X6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvZSWhlUUN3ME2wMlAzQTdibl2= MXHTRW5ITVJ?
LB2241-RCC MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXqU|N7UUN3ME2wMlA{OThibl2= NILZcndUSU6JRWK=
CHL-1 NX3qXJJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvFR|ZzUUN3ME2wMlA{OjRibl2= M4PBcHNCVkeHUh?=
SW1783 M{XZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;TfmlEPTB;MD6wN|M3KG6P MXTTRW5ITVJ?
MEL-JUSO MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\jTWM2OD1yLkCzPVEhdk1? NX\DNoY3W0GQR1XS
HT-29 NYLpbHNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP0XVdkUUN3ME2wMlA1OTNibl2= NVvGbphFW0GQR1XS
SNG-M MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fQeWlEPTB;MD6wOFI2KG6P NFPGOWlUSU6JRWK=
TE-15 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHri[nlKSzVyPUCuNFQ3PCCwTR?= Ml3DV2FPT0WU
HOS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i2emlEPTB;MD6wOFghdk1? NG\PfVJUSU6JRWK=
BB65-RCC NXzVXYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEiyfnpKSzVyPUCuNFUyOiCwTR?= MWrTRW5ITVJ?
HCE-4 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPrNI5KSzVyPUCuNFUzQCCwTR?= MmTCV2FPT0WU
MHH-ES-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2OyVWlEPTB;MD6wOVMyKG6P MnXvV2FPT0WU
RPMI-7951 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLWUW1KSzVyPUCuNFU1OSCwTR?= M1q1TXNCVkeHUh?=
IST-SL2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEW4OEBvVQ>? NYLpeZNxW0GQR1XS
CMK NH\aOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrmTWM2OD1yLkC1PFYhdk1? MoHCV2FPT0WU
GR-ST MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXtUVhKSzVyPUCuNFU6PSCwTR?= M4fW[HNCVkeHUh?=
NALM-6 NXe0eZdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETw[lhKSzVyPUCuNFYzOiCwTR?= NFfOdJFUSU6JRWK=
RPMI-6666 NF7pfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PS[WlEPTB;MD6wOlUzKG6P NU\wd2hQW0GQR1XS
LC-2-ad M2Px[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPyVW1KSzVyPUCuNFY2OyCwTR?= NIL0PXhUSU6JRWK=
ARH-77 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEexNUBvVQ>? NHH5XG9USU6JRWK=
IST-MEL1 M3f4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHNTWM2OD1yLkC3NlYhdk1? MY\TRW5ITVJ?
SW1710 NH\UclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL5TWM2OD1yLkC3OVEhdk1? MVzTRW5ITVJ?
DEL M3zxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fK[GlEPTB;MD6wPFg4KG6P MVvTRW5ITVJ?
AGS MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonvTWM2OD1yLkC5NFIhdk1? MYjTRW5ITVJ?
NCI-H2122 NHP4VHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TRdWlEPTB;MD6wPVQ3KG6P M1zXT3NCVkeHUh?=
HSC-4 M{W4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS1TWM2OD1yLkGwNkBvVQ>? NH3acZFUSU6JRWK=
AM-38 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzLTWM2OD1yLkGyNUBvVQ>? MXnTRW5ITVJ?
769-P MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj6TWM2OD1yLkGyN{BvVQ>? NYHYV2x1W0GQR1XS
RT-112 NHX6WVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DCUGlEPTB;MD6xNlchdk1? M4fFOHNCVkeHUh?=
MCF7 M4jmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTC[JdQUUN3ME2wMlE{PiCwTR?= MoHIV2FPT0WU
IGROV-1 NIK1fXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSzTWM2OD1yLkG0OUBvVQ>? MlLtV2FPT0WU
OCI-AML2 NFTJPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLXTWM2OD1yLkG0O{BvVQ>? NGrjeJhUSU6JRWK=
NCI-H1299 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXMVIVSUUN3ME2wMlE2PyCwTR?= MmHaV2FPT0WU
A431 NHnpenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LCbmlEPTB;MD6xPFMhdk1? MYDTRW5ITVJ?
SW982 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWflU5R6UUN3ME2wMlIyOyCwTR?= NGruUm9USU6JRWK=
BB30-HNC NUTyeWlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[0cmlEPTB;MD6yN|Ehdk1? M4\DOnNCVkeHUh?=
ACN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe3cm1KSzVyPUCuNlQ1KG6P NVv1WmZKW0GQR1XS
647-V M4rufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jTfGlEPTB;MD6yOFghdk1? MV3TRW5ITVJ?
SK-PN-DW NVW0dWR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHEN3dKSzVyPUCuNlY3KG6P M1ux[HNCVkeHUh?=
LCLC-97TM1 M1PEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnOT41TUUN3ME2wMlI3PyCwTR?= MUHTRW5ITVJ?
LB1047-RCC Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne4TWM2OD1yLkK2PUBvVQ>? MoLDV2FPT0WU
A2780 M16xN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMkegcm0> NYP4R|FwW0GQR1XS
C-33-A NVHL[oNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPITWM2OD1yLkK3N{BvVQ>? MUjTRW5ITVJ?
NCI-H2228 NFzXTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK2b5hKSzVyPUCuN|E1KG6P MVLTRW5ITVJ?
TE-5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwM{G2JI5O M4\EdnNCVkeHUh?=
HC-1 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fEV2lEPTB;MD6zNlchdk1? M4PnOHNCVkeHUh?=
SK-MES-1 NXfEU21WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwM{K4JI5O MlzKV2FPT0WU
NCI-H1355 M1fmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHF[lNsUUN3ME2wMlM5OSCwTR?= M{LQcHNCVkeHUh?=
YKG-1 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn61TWM2OD1yLkSxPUBvVQ>? MYnTRW5ITVJ?
RS4-11 M1LPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nLfWlEPTB;MD60N|Mhdk1? M{nJ[XNCVkeHUh?=
Daoy MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[5W2lEPTB;MD60OVYhdk1? MnryV2FPT0WU
A3-KAW M4LFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK1TWM2OD1yLkW1NUBvVQ>? MmXKV2FPT0WU
SK-MEL-30 MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXGV4NKSzVyPUCuOVU1KG6P NILSXYdUSU6JRWK=
U031 MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7hfVBKSzVyPUCuOVY2KG6P M{PHRnNCVkeHUh?=
SK-LMS-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2niUmlEPTB;MD61O|ghdk1? Mn33V2FPT0WU
ES6 NFfiZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwNUi2JI5O MXrTRW5ITVJ?
EoL-1-cell MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr2TIxKSzVyPUCuOlE3KG6P NEHVSYtUSU6JRWK=
NCI-H2009 M4H3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwNkG5JI5O MkDEV2FPT0WU
A4-Fuk M2fuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojTTWM2OD1yLk[yOkBvVQ>? MmroV2FPT0WU
KYSE-270 NHeyU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXa[ZNIUUN3ME2wMlY{PCCwTR?= MkfEV2FPT0WU
SK-LU-1 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\1NmlEPTB;MD62OVUhdk1? MnrEV2FPT0WU
SW872 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\wTWM2OD1yLke2OUBvVQ>? NECyXo1USU6JRWK=
ES8 MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LvPGlEPTB;MD63PEBvVQ>? NYPGeVNLW0GQR1XS
G-402 M{fLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm1eYFKSzVyPUCuO|g1KG6P MkPpV2FPT0WU
ATN-1 M4qwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHJTWM2OD1yLkiwO{BvVQ>? NVXVc|hlW0GQR1XS
DoTc2-4510 NYf3eJBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7mOZpKSzVyPUCuPVAyKG6P MXrTRW5ITVJ?
MES-SA NEj2WoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwOUC1JI5O NVfWbmJlW0GQR1XS
SF268 MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDsPFNKSzVyPUCuPVI4KG6P MVvTRW5ITVJ?
SF539 MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nnZWlEPTB;MT6wNkBvVQ>? M1zFbnNCVkeHUh?=
NB69 M1XCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvZ[ohKSzVyPUGuNFUhdk1? NFvWV2RUSU6JRWK=
8505C M4rY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwME[gcm0> MVvTRW5ITVJ?
CAL-12T MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMEigcm0> NH7teJRUSU6JRWK=
BHY MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwMUSgcm0> NGK2bWZUSU6JRWK=
LB647-SCLC NYO1W2VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDF[FRWUUN3ME2xMlE5KG6P Mn\GV2FPT0WU
CAL-62 NW\hVIFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHONm1KSzVyPUGuNlIhdk1? NUHhWmdoW0GQR1XS
MEG-01 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwMkegcm0> NVnxNGZqW0GQR1XS
MG-63 M4PXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPITWM2OD1zLkOzJI5O MUnTRW5ITVJ?
SW620 NW\SXnRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwM{Wgcm0> NHXzT2VUSU6JRWK=
A388 NWTHZlVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfOO4lKSzVyPUGuN|Yhdk1? NHTic3hUSU6JRWK=
BCPAP NIHQdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rq[GlEPTB;MT60OUBvVQ>? M1TVe3NCVkeHUh?=
P30-OHK NXfodWZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnsWIhKSzVyPUGuOFYhdk1? MWfTRW5ITVJ?
Ca9-22 M2D6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f3emlEPTB;MT61OEBvVQ>? MkTsV2FPT0WU
VMRC-RCZ M37aO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;EUmlEPTB;MT61OEBvVQ>? NYXP[oV4W0GQR1XS
LOXIMVI M3rVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TwemlEPTB;MT62JI5O NEHnUYVUSU6JRWK=
L-540 NH7Dc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPsc4ZKSzVyPUGuOkBvVQ>? Mn[1V2FPT0WU
NTERA-S-cl-D1 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX3VmNWUUN3ME2xMlY1KG6P MXjTRW5ITVJ?
MFH-ino MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G4bmlEPTB;MT62OkBvVQ>? NF;EUmFUSU6JRWK=
Calu-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP2W25[UUN3ME2xMlc{KG6P NYH0WoV3W0GQR1XS
HEL M4\Kcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\1Z25mUUN3ME2xMlc6KG6P MnGxV2FPT0WU
CAL-33 NHnBXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHHTWM2OD1zLki5JI5O MoLtV2FPT0WU
HSC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjmU3ZKSzVyPUGuPVEhdk1? Mn\KV2FPT0WU
KU812 M17MUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LyeGlEPTB;MT65NUBvVQ>? MYLTRW5ITVJ?
EB2 NGj2OmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnpc5dKSzVyPUKuNFEhdk1? MXLTRW5ITVJ?
SR NET1dIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHYZox4UUN3ME2yMlEzKG6P NWqyN2tHW0GQR1XS
NCI-H2087 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmyZXNKSzVyPUKuNVQhdk1? NEHCU5pUSU6JRWK=
H4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJwMUigcm0> MkfsV2FPT0WU
EW-1 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwMkKgcm0> M33YRnNCVkeHUh?=
MC-IXC MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDRb3B4UUN3ME2yMlI3KG6P MXrTRW5ITVJ?
NCI-H727 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jj[GlEPTB;Mj61NUBvVQ>? NUPRT5FxW0GQR1XS
MRK-nu-1 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmzVI06UUN3ME2yMlU4KG6P NY[3WJIyW0GQR1XS
COLO-668 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfwc|B{UUN3ME2yMlY3KG6P NUnTeFZ4W0GQR1XS
CGTH-W-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37mdGlEPTB;Mj63NkBvVQ>? MUTTRW5ITVJ?
CHP-212 NIqwcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7wTWM2OD1{Lke1JI5O NEnBemZUSU6JRWK=
GI-1 NWXpT41WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz1[lFXUUN3ME2yMlc3KG6P MlLIV2FPT0WU
HCC1806 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3wTWM2OD1{LkmxJI5O MUXTRW5ITVJ?
HLE NUm3dW05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNibl2= NX;IT2x7W0GQR1XS
HSC-2 NYX1dHhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HkSGlEPTB;Mz6wN{BvVQ>? NF3YZZRUSU6JRWK=
DMS-273 MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnKTWM2OD1|LkC3JI5O NV\4VFVNW0GQR1XS
DU-4475 NXvYOFZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHuTWM2OD1|LkG0JI5O NUHJfGpbW0GQR1XS
LXF-289 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfhTWM2OD1|LkOxJI5O M1vDRXNCVkeHUh?=
PANC-03-27 NF60enRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrkVJJKSzVyPUOuOVEhdk1? NFPXWldUSU6JRWK=
GAMG MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH0PGJWUUN3ME2zMlc1KG6P Mn3XV2FPT0WU
NCI-H522 NGXsSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH33RWNKSzVyPUSuN|Qhdk1? M1roRXNCVkeHUh?=
SW626 M4Hk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz0[odKSzVyPUSuOFYhdk1? MXHTRW5ITVJ?
HT-144 M2XmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XqOmlEPTB;ND65NkBvVQ>? NVTVNVlPW0GQR1XS
MEL-HO NE\1bnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XjVmlEPTB;NT6xOkBvVQ>? M2HRfHNCVkeHUh?=
BE-13 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnJTWM2OD13LkKxJI5O NWTBZZhHW0GQR1XS
VA-ES-BJ NHPqWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK0Xno6UUN3ME21MlI3KG6P MYDTRW5ITVJ?
NCI-H441 M3TBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnpdm94UUN3ME21MlYhdk1? MoHsV2FPT0WU
KP-4 NE\Oe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfvUmJKSzVyPUWuOlEhdk1? NYXZ[VB4W0GQR1XS
LoVo NIL3W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTVwN{Ggcm0> M{nRZXNCVkeHUh?=
HT-1080 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\STWM2OD13LkizJI5O MV\TRW5ITVJ?
GB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnqTWM2OD13Lki0JI5O M{nHUXNCVkeHUh?=
IA-LM NWLFVI5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3ON2hVUUN3ME21MlkyKG6P NFrNTnlUSU6JRWK=
8-MG-BA NYfhOo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTvVXNKSzVyPUWuPVMhdk1? M3H1WHNCVkeHUh?=
SK-HEP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[1[mZ7UUN3ME22MlE1KG6P NGLt[41USU6JRWK=
697 M2LhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvmRZNKSzVyPU[uNlUhdk1? NEjtV2lUSU6JRWK=
KYSE-450 M3HqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjOOZJiUUN3ME22MlMzKG6P M1XMTHNCVkeHUh?=
HCC2998 NGm3UVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTZwM{Sgcm0> NGjyW5hUSU6JRWK=
HD-MY-Z M2rv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rWWWlEPTB;Nj62PEBvVQ>? NYPIOI5RW0GQR1XS
OS-RC-2 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLEOWRlUUN3ME22MlY5KG6P MVHTRW5ITVJ?
SF126 M1nBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nlOmlEPTB;Nz6wOUBvVQ>? NGCxXYNUSU6JRWK=
Ca-Ski MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULNUG1YUUN3ME23MlA6KG6P MVXTRW5ITVJ?
NCI-H358 NFXXWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrRUJZKSzVyPUeuNVYhdk1? M4HsSHNCVkeHUh?=
J82 NWLKV2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTdwNEGgcm0> NH;tN|lUSU6JRWK=
NCI-H2342 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnNfnNKSzVyPUeuOlMhdk1? Mn;iV2FPT0WU
OVCAR-8 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTdwOTDuUS=> MkDyV2FPT0WU
TE-8 NILtZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjq[olKSzVyPUigcm0> NUD3clhzW0GQR1XS
ETK-1 NIPne49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXrbYpKSzVyPUiuNFghdk1? NYT4ZYhUW0GQR1XS
HAL-01 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRThwMjDuUS=> M4rpfnNCVkeHUh?=
KYSE-150 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PTUWlEPTB;OD60O{BvVQ>? NUC2VZI6W0GQR1XS
NCI-H810 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHkOoRQUUN3ME24MlU3KG6P NUnoXnNYW0GQR1XS
ONS-76 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRThwNkigcm0> NWjuOWp4W0GQR1XS
NMC-G1 NYHUNmVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwN{[gcm0> NECzc2tUSU6JRWK=
C3A NELxNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK4WYtKSzVyPUiuPFQhdk1? NUTSd4lMW0GQR1XS
PA-1 M4TEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37nT2lEPTB;OD65PUBvVQ>? NWXSNnZVW0GQR1XS
SH-4 M37xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XEVmlEPTB;OT6wNkBvVQ>? MVTTRW5ITVJ?
EFO-27 NWnPUVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfoTWM2OD17LkC1JI5O M3fkPHNCVkeHUh?=
CAPAN-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7rTWM2OD17LkKzJI5O M{S0[XNCVkeHUh?=
DU-145 NFPBfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT0TWM2OD17LkK5JI5O NFnDfJdUSU6JRWK=
A101D NILhU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jCXWlEPTB;OT6zO{BvVQ>? NVvOWXM4W0GQR1XS
ST486 NUDCTINjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;IRWlEPTB;OT60NUBvVQ>? NWHhNopiW0GQR1XS
NCI-H1437 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HZbGlEPTB;OT60NkBvVQ>? NV6xSHZZW0GQR1XS
HGC-27 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTlwNjDuUS=> NEPvXFhUSU6JRWK=
8305C NEfQ[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf5TWM2OD17Lk[0JI5O M4eyS3NCVkeHUh?=
OCUB-M MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDxO5FnUUN3ME2xNE4xOyCwTR?= MVfTRW5ITVJ?
COLO-679 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFyLkC3JI5O MWHTRW5ITVJ?
Detroit562 M1HNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFyLkSyJI5O MV3TRW5ITVJ?
A204 NWTmdoZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFzLkG2JI5O M3zRcHNCVkeHUh?=
NCI-H1734 NYDFTGVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPCTnJHUUN3ME2xNU4zQSCwTR?= MnHEV2FPT0WU
MC-CAR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3QTWM2OD1zMT61PEBvVQ>? MlzPV2FPT0WU
NCI-H2170 NVPMd2tET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPZTWM2OD1zMT65O{BvVQ>? MVjTRW5ITVJ?
NCI-SNU-5 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XVdWlEPTB;MUKuNVMhdk1? MnjUV2FPT0WU
HCE-T NV\0flRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfxdXRlUUN3ME2xNk41OiCwTR?= NXTRSVhsW0GQR1XS
KYSE-180 NV\rZVBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWyXItKSzVyPUGyMlgyKG6P MYnTRW5ITVJ?
C8166 NGrkRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF|LkC4JI5O M{DheXNCVkeHUh?=
NCI-H460 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC0[HZKSzVyPUGzMlU1KG6P Mmj1V2FPT0WU
SNU-449 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTyOFJLUUN3ME2xN{44PyCwTR?= NGm0bXNUSU6JRWK=
MDA-MB-468 M1LsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TZdWlEPTB;MUSuNVIhdk1? MXzTRW5ITVJ?
COR-L23 M2SyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\vNZJKSzVyPUG0MlE{KG6P MWjTRW5ITVJ?
CTV-1 NH21fYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jGZmlEPTB;MUSuNVQhdk1? NEjFdJNUSU6JRWK=
BL-41 NF7xbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XmXmlEPTB;MUSuN|chdk1? NUDL[ZkyW0GQR1XS
IGR-1 NVe4T29jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7zZnI5UUN3ME2xOE41OiCwTR?= MkWwV2FPT0WU
TK10 NXrUNohbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIroZ|BKSzVyPUG0MlQ6KG6P M2TO[nNCVkeHUh?=
REH MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf0SGZKSzVyPUG0MlUyKG6P MYjTRW5ITVJ?
LU-139 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELXWJhKSzVyPUG0MlU6KG6P NYXWd4pFW0GQR1XS
KP-N-YS Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjHTWM2OD1zND65O{BvVQ>? M3zabnNCVkeHUh?=
PANC-10-05 NVfOS3lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DVNmlEPTB;MUWuN|ghdk1? NHnv[HZUSU6JRWK=
HL-60 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vaN2lEPTB;MUWuOlkhdk1? M3vVdnNCVkeHUh?=
T84 M1;wO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW2THJGUUN3ME2xOU46PiCwTR?= MlTFV2FPT0WU
RPMI-8226 NHHXdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF4LkCyJI5O MYDTRW5ITVJ?
UM-UC-3 M2fVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnjTWM2OD1zNj6xOkBvVQ>? NGraV3hUSU6JRWK=
TE-10 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjLRpB1UUN3ME2xOk4zOSCwTR?= NFP5b2NUSU6JRWK=
CAL-148 NHXmemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTmNldxUUN3ME2xO{4zOyCwTR?= MUXTRW5ITVJ?
BV-173 NX;Db21[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\sOIdKSzVyPUG3MlI4KG6P NX7X[5ZpW0GQR1XS
Calu-3 NVqxS|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT0TWM2OD1zNz6yPUBvVQ>? NFPG[3pUSU6JRWK=
RPMI-2650 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vsW2lEPTB;MUeuOVkhdk1? MXzTRW5ITVJ?
MKN45 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;SUmlEPTB;MUeuO|Mhdk1? NHLP[ldUSU6JRWK=
NUGC-3 NYjSPYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfITWM2OD1zOD6zOEBvVQ>? MkLSV2FPT0WU
NCI-H520 NGLBSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3xVJRKSzVyPUG4Mlc4KG6P MX\TRW5ITVJ?
CCRF-CEM NUfLSpI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfSTG9KSzVyPUG4Mlg2KG6P MlPYV2FPT0WU
NCI-H2405 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7sTWM2OD1zOT6xJI5O MYLTRW5ITVJ?
ES7 NWLOO2NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PnSWlEPTB;MUmuO|Yhdk1? NEDlc5RUSU6JRWK=
BPH-1 M4P2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nNbWlEPTB;MkCuNlghdk1? MVjTRW5ITVJ?
SAS MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\MNpVIUUN3ME2yNE42KG6P MnnWV2FPT0WU
HuCCT1 NYHkZ2YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LtUmlEPTB;MkCuOVghdk1? MX\TRW5ITVJ?
LOUCY MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXRd2lKSzVyPUKwMlY3KG6P MnHXV2FPT0WU
NCI-H292 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;wNZFNUUN3ME2yNE44QSCwTR?= MXjTRW5ITVJ?
G-361 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnSTWM2OD1{MT6wO{BvVQ>? NV;yZo9TW0GQR1XS
M059J NFjxV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCxTWM2OD1{MT6wPEBvVQ>? MmnVV2FPT0WU
NCI-H1651 NFXhZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\ZNWdKSzVyPUKxMlEyKG6P MlTpV2FPT0WU
KALS-1 NU\uPGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS1TWM2OD1{MT6zPUBvVQ>? NGHoXodUSU6JRWK=
DJM-1 NYj3fGdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvVZXFKSzVyPUKxMlU6KG6P NXK1NphzW0GQR1XS
AU565 NI\lb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJzLkizJI5O MXHTRW5ITVJ?
HCC38 NXP5cmpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[3eGZ6UUN3ME2yNU46PSCwTR?= NHzjO2RUSU6JRWK=
U251 NI\LXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f4SGlEPTB;MkKuNlchdk1? NH:xOI9USU6JRWK=
ABC-1 M4jnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LZSWlEPTB;MkKuOlUhdk1? M3roXXNCVkeHUh?=
SK-NEP-1 NFvP[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnTUZlKSzVyPUKyMlk{KG6P NFnPPJhUSU6JRWK=
CESS MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\hNYZXUUN3ME2yN{4yQSCwTR?= M2K4eXNCVkeHUh?=
MIA-PaCa-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjvOGNKSzVyPUKzMlM3KG6P Mn;wV2FPT0WU
SUP-T1 NXHpNnl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHoTXBKSzVyPUKzMlQ4KG6P MoW5V2FPT0WU
L-428 NXniPWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnjfmhGUUN3ME2yN{43OiCwTR?= MXTTRW5ITVJ?
SW954 NEXSRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ|Lk[4JI5O M2rTW3NCVkeHUh?=
HO-1-N-1 NWH0OZk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvmcndKSzVyPUKzMlc4KG6P MYjTRW5ITVJ?
CHP-126 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTDTWM2OD1{ND6xOEBvVQ>? M17SUHNCVkeHUh?=
HMV-II NYe5RVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ2LkO0JI5O MUPTRW5ITVJ?
NB10 M1vuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTBe4REUUN3ME2yOE4{PyCwTR?= NFHBO4hUSU6JRWK=
A172 M1u5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7XNnE1UUN3ME2yOE44OSCwTR?= NXLpWVFOW0GQR1XS
MONO-MAC-6 Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G5dWlEPTB;MkSuPFQhdk1? NF\CPGFUSU6JRWK=
NCI-H1650 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHqSINwUUN3ME2yOU41KG6P NIS4OnNUSU6JRWK=
NH-12 M4fTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3rdVlPUUN3ME2yOU42KG6P MX3TRW5ITVJ?
ML-2 NILmO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzXZpFtUUN3ME2yOU44PCCwTR?= M2nKR3NCVkeHUh?=
MZ2-MEL M{jRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO4Zmt7UUN3ME2yOk4zOiCwTR?= NHry[W1USU6JRWK=
COLO-684 NEjpO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ4LkSxJI5O MXrTRW5ITVJ?
HuP-T4 NGW1VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M322PWlEPTB;MkeuN{BvVQ>? M{TidXNCVkeHUh?=
SW837 NIPYeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILo[WRKSzVyPUK3MlYzKG6P NETKR|BUSU6JRWK=
MDA-MB-231 NVTab5VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ5Lke4JI5O M{fIb3NCVkeHUh?=
KYSE-140 NVLVdFgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyyTWM2OD1{Nz65NUBvVQ>? NIDS[lVUSU6JRWK=
NOMO-1 M3XZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zGPWlEPTB;MkiuOlghdk1? Ml\6V2FPT0WU
GP5d M1j5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m3b2lEPTB;MkiuO|Ihdk1? NE\4TIJUSU6JRWK=
COR-L105 NVnTWmlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ7LkSyJI5O NXznb4Q5W0GQR1XS
LS-411N NGLPc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJ7Lki4JI5O M4rTPXNCVkeHUh?=
NY MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYroWIdRUUN3ME2zNE4yQCCwTR?= NH76d|NUSU6JRWK=
NCI-H2030 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfrb|U6UUN3ME2zNE41PSCwTR?= MnfkV2FPT0WU
CCF-STTG1 MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNzLkSyJI5O NXvsb2xYW0GQR1XS
NCI-H1703 NYC4U21pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNzLke4JI5O Ml\DV2FPT0WU
TUR MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrNcZVKSzVyPUOyMlA{KG6P NF3vc29USU6JRWK=
NOS-1 NGDESllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHXT2NSUUN3ME2zNk41PCCwTR?= NWjLeZhQW0GQR1XS
A2058 NGj1PJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLIcYlKSzVyPUOyMlg{KG6P MVrTRW5ITVJ?
LCLC-103H MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV33R4dzUUN3ME2zN{4zPSCwTR?= NX21bYx3W0GQR1XS
NCI-H510A NHjtTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXHTWM2OD1|Mz6yO{BvVQ>? MXHTRW5ITVJ?
BC-1 NVXzNXBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[5c4hEUUN3ME2zN{44PyCwTR?= M{PMSHNCVkeHUh?=
SK-CO-1 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrOTWM2OD1|ND6wNUBvVQ>? NHHrboFUSU6JRWK=
A673 M{LVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzsTWM2OD1|ND6xO{BvVQ>? M13mbXNCVkeHUh?=
VM-CUB-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjFfIdKSzVyPUO0MlY6KG6P MYjTRW5ITVJ?
HH M2DWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\oWXFKSzVyPUO1MlA3KG6P M33neHNCVkeHUh?=
CAL-27 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN3LkG2JI5O MmKxV2FPT0WU
NEC8 NH[3T3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYntd|Y1UUN3ME2zOU4{PyCwTR?= M{LNTHNCVkeHUh?=
BxPC-3 NH3RV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq5TWM2OD1|Nj65NUBvVQ>? NFTQb4xUSU6JRWK=
SNB75 NYSxbI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j0VmlEPTB;M{euNlQhdk1? NGf0T3dUSU6JRWK=
NB13 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;XTWM2OD1|OD6yN{BvVQ>? Ml\zV2FPT0WU
SK-OV-3 Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj1O2ZKSzVyPUO4Mlc1KG6P NYXmOHRUW0GQR1XS
ME-180 M{HPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDHTWM2OD1|OD64JI5O MXXTRW5ITVJ?
JiyoyeP-2003 NYrUc25NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHZcGdKSzVyPUO5MlM5KG6P MYfTRW5ITVJ?
LU-134-A MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPWTWM2OD12MD6wNkBvVQ>? M4C0eXNCVkeHUh?=
LS-123 NWXyO5BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fzfGlEPTB;NECuNlghdk1? MkPyV2FPT0WU
COLO-800 NYPRbXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHMTWM2OD12MD61OkBvVQ>? NXvLNJdIW0GQR1XS
LB831-BLC NVz6T3duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTRzLki1JI5O M2HjdnNCVkeHUh?=
NCI-H747 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPRN4ZKSzVyPUSyMlI5KG6P MXnTRW5ITVJ?
MZ7-mel NIf6OpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S1Z2lEPTB;NEKuOlYhdk1? NXjB[oV3W0GQR1XS
GT3TKB MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTR{LkeyJI5O M3zjXHNCVkeHUh?=
MOLT-16 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTR|LkC1JI5O NXm1e4lzW0GQR1XS
23132-87 M4fmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PFZ2lEPTB;NEOuNFUhdk1? M3v1VXNCVkeHUh?=
PF-382 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrxV5FKSzVyPUS0MlIzKG6P M36yeHNCVkeHUh?=
ES3 M33hcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofoTWM2OD12ND62JI5O NHjBW|BUSU6JRWK=
SW756 NInoelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnJW4ZKSzVyPUS1MlE1KG6P MULTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 順序で溶剤を入れること:
water warming
14mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4

CAS No. 95058-81-4
保管
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis信号経路図

相関DNA/RNA Synthesis製品

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID